Cancer name Kidney Renal Clear Cell Carcinoma
Cancer Type KIRC
Immunotherapy type Oncolytic viruses
Treatment WR.TK-HPGD+
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CTLs
Official Symbol Cytotoxic T cell
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Oncolytic viral infection alone,therefore, appears capable of inducing an inflammatory response and initial immune activation, whereas HPGD expression may be required to prevent premature shutdown of the immune response before full induction of adaptive immunity. This is supported by the observation that at 7 days after treatment WR.TK-HPGD+ had induced a 4-fold increase in the number of anti-tumor cytotoxic T lymphocytes (CTLs) in the spleen relative to WR.TK-treatment.
PMID 27374223
Title Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy